Traditionally, endocrine therapy was the first-line treatment for metastatic HR-positive, HER2-negative breast cancers, but the development of resistance towards endocrine therapy would subsequently necessitate chemotherapy [7]. This evidence concerns the gene ERBB2 and breast carcinoma.